Ravi Shankar Prasad Singh

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman et al. · Clinical Pharmacology & Therapeutics · 2022 · 156 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Comparison of various international guidelines for analytical method validation

Sajeev Chandran, Ravi Shankar Prasad Singh · ˜Die œPharmazie · 2007 · 154 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmaceutics +16

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar et al. · Drug Metabolism and Disposition · 2022 · 116 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Spencer I. Danto, Negin Shojaee, Ravi Shankar Prasad Singh et al. · Arthritis Research & Therapy · 2019 · 61 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10